• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

原发性丛状动脉病中的血栓性病变。相似的发病机制还是并发症?

Thrombotic lesions in primary plexogenic arteriopathy. Similar pathogenesis or complication?

作者信息

Wagenvoort C A, Mulder P G

机构信息

Department of Pathology, Erasmus University, Rotterdam, the Netherlands.

出版信息

Chest. 1993 Mar;103(3):844-9. doi: 10.1378/chest.103.3.844.

DOI:10.1378/chest.103.3.844
PMID:8449079
Abstract

In 78 patients with primary plexogenic arteriopathy (PPA), numbers of organized and recanalized thrombi were established in histologic slides of lung tissue and expressed per square centimeter of section. Three control groups of ten individuals each were used: normal, plexogenic arteriopathy secondary to ventricular septal defect, and hypoxic pulmonary hypertension. Thrombotic lesions were scarce in normal individuals but numerous in all three groups with pulmonary hypertension. There is also a positive correlation with age. Thrombotic lesions are absent or scarce in children but more common in adults, even in normal control subjects and particularly in pulmonary hypertension by whatever cause. In PPA there is likely to be a relation with the duration of illness but not with the stage of the disease. The complete pattern of plexogenic arteriopathy may develop in the absence of thrombotic lesions, which clearly are not essential for its pathogenesis. Rather than being part specifically of PPA, as sometimes suggested, thrombotic lesions complicate various types of hypertensive pulmonary vascular disease. Apparently the combination of sustained pulmonary hypertension and age, possibly through endothelial injury, may elicit thrombosis and its sequelae, which in turn may aggravate the pulmonary arterial pressure.

摘要

在78例原发性丛状动脉病(PPA)患者中,对肺组织组织学切片中机化和再通血栓的数量进行了测定,并以每平方厘米切片面积表示。使用了三个对照组,每组10人:正常组、继发于室间隔缺损的丛状动脉病组和低氧性肺动脉高压组。正常个体的血栓性病变很少,但在所有三组肺动脉高压患者中都很多。血栓性病变与年龄也呈正相关。儿童不存在或很少有血栓性病变,但在成年人中更常见,即使在正常对照者中也是如此,尤其是在任何原因引起的肺动脉高压患者中。在PPA中,血栓性病变可能与病程有关,但与疾病阶段无关。丛状动脉病的完整模式可能在没有血栓性病变的情况下发展,显然血栓性病变对其发病机制并非必不可少。血栓性病变并非如有时所认为的那样是PPA特有的一部分,而是使各种类型的高血压性肺血管疾病复杂化。显然,持续的肺动脉高压和年龄的结合,可能通过内皮损伤,引发血栓形成及其后遗症,进而可能加重肺动脉压力。

相似文献

1
Thrombotic lesions in primary plexogenic arteriopathy. Similar pathogenesis or complication?原发性丛状动脉病中的血栓性病变。相似的发病机制还是并发症?
Chest. 1993 Mar;103(3):844-9. doi: 10.1378/chest.103.3.844.
2
Comparison of primary plexogenic arteriopathy in adults and children. A morphometric study in 40 patients.成人与儿童原发性丛状动脉病的比较。对40例患者的形态计量学研究。
Br Heart J. 1985 Oct;54(4):428-34. doi: 10.1136/hrt.54.4.428.
3
Morphological substrate for the reversibility and irreversibility of pulmonary hypertension.肺动脉高压可逆性与不可逆性的形态学基础。
Eur Heart J. 1988 Sep;9 Suppl J:7-12. doi: 10.1093/eurheartj/9.suppl_j.7.
4
Pulmonary vascular disease in secundum atrial septal defect with pulmonary hypertension.
Chest. 1986 May;89(5):694-8. doi: 10.1378/chest.89.5.694.
5
Reversibility of plexogenic pulmonary arteriopathy following banding of the pulmonary artery.肺动脉束带术后丛状肺血管病的可逆性
J Thorac Cardiovasc Surg. 1984 Jun;87(6):876-86.
6
Altered arterial expression patterns of inducible and endothelial nitric oxide synthase in pulmonary plexogenic arteriopathy caused by congenital heart disease.先天性心脏病所致肺丛状动脉病中诱导型一氧化氮合酶和内皮型一氧化氮合酶的动脉表达模式改变
Am J Respir Crit Care Med. 2001 May;163(6):1493-9. doi: 10.1164/ajrccm.163.6.9908137.
7
S100A4/Mts1 produces murine pulmonary artery changes resembling plexogenic arteriopathy and is increased in human plexogenic arteriopathy.S100A4/Mts1会引发类似于丛状动脉病的小鼠肺动脉变化,且在人类丛状动脉病中会增加。
Am J Pathol. 2004 Jan;164(1):253-62. doi: 10.1016/S0002-9440(10)63115-X.
8
Pulmonary hypertension: a cellular basis for understanding the pathophysiology and treatment.肺动脉高压:理解病理生理学和治疗方法的细胞基础
J Am Coll Cardiol. 1989 Sep;14(3):545-50. doi: 10.1016/0735-1097(89)90090-9.
9
Age-related changes among 25 patients with congenital cardiac left-to-right shunts and irreversible plexogenic pulmonary arteriopathy.25例先天性心脏左向右分流合并不可逆性丛状肺血管病患者的年龄相关变化。
Cardiovasc Pathol. 2008 Nov-Dec;17(6):382-91. doi: 10.1016/j.carpath.2008.02.005.
10
Plexogenic pulmonary arteriopathy: significance of medial thickness with respect to advanced pulmonary vascular lesions.丛状肺血管病:中膜厚度在晚期肺血管病变中的意义
Am J Pathol. 1981 Oct;105(1):70-5.

引用本文的文献

1
Angiopoietin-2 and D-dimer add prognostic information to clinical risk in pulmonary arterial hypertension.血管生成素-2和D-二聚体可为肺动脉高压的临床风险增加预后信息。
JHLT Open. 2024 Nov 6;7:100178. doi: 10.1016/j.jhlto.2024.100178. eCollection 2025 Feb.
2
Clinical evaluation of nebulized verapamil in out-patients with pulmonary hypertension secondary to chronic obstructive pulmonary disease.雾化维拉帕米治疗慢性阻塞性肺疾病相关性肺动脉高压患者的临床评估。
Clin Respir J. 2022 Dec;16(12):802-811. doi: 10.1111/crj.13551. Epub 2022 Nov 6.
3
Platelets, extracellular vesicles and coagulation in pulmonary arterial hypertension.
血小板、细胞外囊泡与肺动脉高压中的凝血
Pulm Circ. 2021 Jun 4;11(3):20458940211021036. doi: 10.1177/20458940211021036. eCollection 2021 Jul-Sep.
4
Detection of pulmonary artery atherosclerosis by FDG-PET/CT: a new observation.通过氟代脱氧葡萄糖正电子发射断层显像/计算机断层扫描(FDG-PET/CT)检测肺动脉粥样硬化:一项新观察。
Am J Nucl Med Mol Imaging. 2020 Jun 15;10(3):127-134. eCollection 2020.
5
Portuguese validation of the Cambridge pulmonary hypertension outcome review (CAMPHOR) questionnaire.剑桥肺动脉高压结局评估(CAMPHOR)问卷的葡萄牙语验证
Health Qual Life Outcomes. 2016 Jul 26;14(1):110. doi: 10.1186/s12955-016-0513-8.
6
Current Approach to the Diagnosis and Management of Portopulmonary Hypertension.门静脉高压性肺动脉高压的当前诊断与管理方法
Curr Gastroenterol Rep. 2016 Jun;18(6):29. doi: 10.1007/s11894-016-0504-2.
7
Anticoagulation in pulmonary arterial hypertension: Contemporary data from COMPERA registry.肺动脉高压中的抗凝治疗:来自COMPERA注册研究的当代数据。
Glob Cardiol Sci Pract. 2014 Jun 18;2014(2):48-52. doi: 10.5339/gcsp.2014.25. eCollection 2014.
8
Current clinical management of pulmonary arterial hypertension.肺动脉高压的临床治疗现状。
Circ Res. 2014 Jun 20;115(1):131-147. doi: 10.1161/CIRCRESAHA.115.303827.
9
Physiologic and molecular consequences of endothelial Bmpr2 mutation.内皮细胞 Bmpr2 突变的生理和分子后果。
Respir Res. 2011 Jun 22;12(1):84. doi: 10.1186/1465-9921-12-84.
10
A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension.多激酶抑制剂索拉非尼用于肺动脉高压患者的剂量/交叉研发研究。
Clin Pharmacol Ther. 2010 Mar;87(3):303-10. doi: 10.1038/clpt.2009.217. Epub 2009 Dec 9.